TomoTherapy signs purchasing agreement with GNYHA Services

TomoTherapy Incorporated (NASDAQ: TOMO), maker of the TomoTherapy® treatment system for advanced, CT-guided radiation therapy, announced today that it has signed an equipment supply group purchasing agreement with GNYHA Services, Inc. Pursuant to this agreement, TomoTherapy technology will be made available at contracted rates to more than 220 member hospitals in New York, New Jersey, Pennsylvania and Puerto Rico.

Fred Robertson, TomoTherapy CEO, said, "It is an honor to work with GNYHA Services, the largest regional group purchasing organization in the country. GNYHA Services is committed to helping its member hospitals improve healthcare quality. The TomoTherapy treatment system will certainly help GNYHA Services fulfill this goal."

GNYHA Services was founded in 1978 as the for-profit group purchasing arm of the Greater New York Hospital Association (GNYHA), a trade association that dates back to 1904.

In 1996, GNYHA Services partnered with Premier Purchasing Partners, L.L.P., one of the largest voluntary healthcare alliances in the U.S., to offer unsurpassed value and financial return to its members through access to Premier's comprehensive contract portfolio. Through the oversight of Giuliani Partners, L.L.C., this relationship was extended in 2004, with a renewed focus on flexibility in regionally-enhanced and direct contracting by GNYHA.

Source:

TomoTherapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Temozolomide and radiation combination improves survival in low-grade glioma patients